
Benitec Biopharma Inc.: stock overview
Price
$7.92
November 20, 2026Market cap $392M
What Ploutos Investor adds for Benitec Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from FY2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
It holds more cash than debt, by $176M. It pays no dividend.
From its SEC filings (latest fiscal year to June 30, 2026) and the price of November 20, 2026.
Its SEC filings- Market cap
- $392M
- 49.49M shares
- P/E
- –
- Revenue, 12 months
- –
- Net margin
- –
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
Fiscal years in figures
BNTC's revenue, profit, cash flow and dividend with each year-end price, from FY2019 to FY2023, 5 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $307M
- $392M
- Enterprise value
- $215M
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B 3-year median: 2.6
- 2.3
- FCF yield 3-year median: -7.7%
- –
- Earnings yield 3-year median: -9.0%
- –
Profitability
- Net margin
- –
- ROIC
- -22.9%
- ROIC, 5-year average
- -145.9%
- ROE
- -30.5%
Growth
- Revenue, yearly change
- -100.0%
- EPS, yearly change
- –
- FCF, yearly change
- –
The yearly change compares FY2026 with FY2025.
Balance sheet
- Cash
- $176M
- Total debt
- $642.0K
- Of which operating leases
- $642.0K
- Net cash
- $176M
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- 19.62
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +32.9%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Benitec Biopharma Inc.
- CIK
- 1808898
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- June 30, 2026
- Reporting currency
- USD
- Shares
- 49.49M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with BNTC
- JNJJohnson & Johnson+0,00%Compare with BNTC
- ABBVAbbVie+0,00%Compare with BNTC
- UNHUnitedHealth+0,00%Compare with BNTC
- MRKMerck & Company+0,00%Compare with BNTC
- AMGNAmgen+0,00%Compare with BNTC
- TMOThermo Fisher Scientific+0,00%Compare with BNTC
- ABTAbbott Laboratories+0,00%Compare with BNTC
The full analysis
What do Benitec Biopharma's filings show?
These are Benitec Biopharma's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is BNTC's market cap?
Benitec Biopharma Inc.'s market cap is $392M, at a price of $7.92 on November 20, 2026 and 49.49M shares.
Does BNTC pay a dividend?
No. Benitec Biopharma paid no regular dividend over the last 12 months.
Where do the figures come from?
From Benitec Biopharma Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.